BioSpace News Archive

Impact of new SARS-CoV-2 variants supports specification of select strains for anticipated case-driven interim analysis in pivotal Phase 2b/3 study Progress in Phase 2a trial in older adults in Peru and Panama enables addition of secondary vaccine efficacy endpoint CureVac reaffirms intention to apply for formal market authorization in Q2 2021

Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company with a continuous delivery platform of approved drugs in novel indications, announced today that it has completed a Type B pre-Investigational New Drug (“pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding Starton’s proposed clinical studies for STAR-LLD in the treatment of chronic lymphocytic leukemia (CLL).

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com

Sirtex Medical (“Sirtex”) , a leading manufacturer of targeted liver cancer therapies, announced full FDA approval of the DOORwaY 90 Study, a trial evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres ® Y-90 resin microspheres in patients with unresectable hepatocellular carcinoma

Lantheus Announces Presentation Featuring AZEDRA ® (iobenguane I 131) at ENDO 2021 - Statistically Significant Correlation Between Biomarker Responses and Objective Tumor Response -

Jushi Holdings Inc. (“Jushi” or the “Company”)(CSE: JUSH) (OTCMKTS: JUSHF), a vertically integrated, multi-state cannabis operator, announced that it expects to report its financial results for the fourth quarter and full year ended December 31, 2020 before the market opens on Thursday, April 29, 2021.

Registration is open for golf events at premier championship courses including the Arizona Biltmore Golf Club, Eugene Country Club, The Golf Club at Newcastle, and Western Lakes Golf Club, in support of MDA

Xylonix, a Singapore-based biotech company, has developed a new immunity drug (010DS-Zn) that demonstrates potential for treating a variety of solid cancers and COVID-19’s post-recovery complications, which include heart damage, diabetes and multi-system inflammatory syndrome in children (MIS-C).

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that Journey Medical Corporation (“Journey Medical”), a partner company of Fortress, in-licensed and launched an oral isotretinoin under the brand name Accutane® (isotretinoin capsules USP) in the U.S.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data demonstrating its StemVacs-V iPSC derived dendritic cell product stimulates two distinct immunological mechanisms responsible for its anticancer activity in animal studies.